Form 4 for AKBA Akebia Therapeutics, Inc.

Accepted 2024-06-10 00:00:00 ET · period of report 2024-06-06 · accession 0001562180-24-004910 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2024-06-10	2024-06-06	AKBA	Wolf Myles	Dir	A - Grant	$0.00	+30.0K	97.7K	+44%	$0
D	2024-06-10	2024-06-06	AKBA	Wolf Myles	Dir	A - Grant	$0.00	+45.0K	45.0K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-06-06	A	A	30,000	$0.00	97,681	D	—	—	(F1) The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Third Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer.
2	Derivative	Stock Option (Right to buy)	2024-06-06	A	A	45,000	$0.00	45,000	D	$1.07 · 2025-06-06 to 2034-06-06	45,000 Common Stock	(F2) The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continued service to the Issuer.